Jubilant Pharmova Limited

530019

INE700A01033

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:19:35 2024-04-25 am EDT			5-day change	1st Jan Change
676.6 ^INR	-0.86%		-3.56%	+23.99%

Apr. 25	Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA	MT
Apr. 17	Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility	MT

Jubilant Pharmova Limited acquired 25.21% interest in SPV Laboratories Pvt Ltd. for INR 87.5 million.

April 01, 2022

Jubilant Pharmova Limited (BSE:530019) entered into an agreement to acquire 25.21% interest in SPV Laboratories Pvt Ltd for INR 87.5 million on April 1, 2022. For the year 2020-2021, SPV had revenue of INR 18.7 million and EBITDA of INR -13.5 million.

Jubilant Pharmova Limited (BSE:530019) completed the acquisition of 25.21% interest in SPV Laboratories Pvt Ltd on April 1, 2022.

Latest news about Jubilant Pharmova Limited

Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA	Apr. 24	MT
Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility	Apr. 17	MT
India's Jubilant Pharmova posts quarterly profit	Feb. 02	RE
Jubilant Pharmova Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 02	CI
Jubilant Ingrevia Redeems INR1 Billion at Maturity Date	Nov. 15	MT
Jubilant Pharmova Unit Gets US FDA's Approval for Technetium Sulfur Colloid Injection	Nov. 13	MT
Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023	23-10-27	CI
Jubilant Pharmova Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-27	CI
Domino's India operator Jubilant beats Q2 profit estimates on cheaper launches	23-10-25	RE
Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2023, Payable on or Before September 29, 2023	23-08-07	CI
Jubilant Pharmova Limited Recommends Dividend for the Financial Year Ended March 31, 2023	23-07-31	CI
Jubilant Pharmova's Consolidated Profit Plunges in Fiscal Q1	23-07-20	MT
Jubilant Pharmova Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-19	CI
Indian shares set for flat start ahead of key earnings	23-07-18	RE
Jubilant Pharmova Names Managing Director	23-05-30	MT
Late Rally Led by Consumer Goods, Financials Lifts Indian Equities to Close Higher	23-05-30	MT
Jubilant Pharmova CFO Steps Down	23-05-30	MT
Jubilant Pharmova Limited Announces Change in Directorate	23-05-30	CI
Jubilant Pharmova Limited Announces CFO Changes	23-05-30	CI
INDIA STOCKS-Indian shares rise to five-month high on improved global cues	23-05-30	RE
Jubilant Pharmova Limited Recommends Dividend for the Financial Year Ended March 31, 2023	23-05-29	CI
Jubilant Pharmova Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
Jubilant Pharmanova's Canadian Arm Gets CA$24 Million Loan for Capacity Expansion	23-03-17	MT
Jubilant Pharmova Gets VAI from US FDA for API Manufacturing Facility in Karnataka, India	23-03-08	MT
Jubilant Pharmova Limited Appoints Shirish G. Belapure as Additional Director (Non-Executive, Independent)	23-03-08	CI

Chart Jubilant Pharmova Limited

Duration

Period

More charts

Company Profile

Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.

Sector

Pharmaceuticals

Calendar

2024-05-30 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
JUBILANT PHARMOVA LIMITED	+23.99%	1.3B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals